Dr. Levine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 E 102nd St
New York, NY 10029Phone+1 212-241-6756
Education & Training
- Memorial Sloan Kettering Cancer Center1992 - 1995
- Children's Hospital Los AngelesResidency, Pediatrics, 1989 - 1992
- Eastern Virginia Medical SchoolClass of 1989
Certifications & Licensure
- CA State Medical License 1990 - Present
- FL State Medical License 2020 - Present
- NY State Medical License 1992 - 2026
- PA State Medical License 2016 - 2018
- MI State Medical License 1995 - 2017
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants Start of enrollment: 2002 Sep 01
- The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Start of enrollment: 2003 Oct 01
- Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) Start of enrollment: 2004 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk
Transplantation and Cellular Therapy. 2024-11-26 - Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.Carlos A Ortega Rios, Muna Qayed, Aaron M Etra, Ran Reshef, Richard Newcomb
Transplantation and Cellular Therapy. 2024-11-01 - Verification of the Prediction Accuracy of a Biomarker-Based Prognostic for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Cell T...Santosh Putta, Bradford Young, Polly Pine, Ju Shi, Vian Amber
Transplantation and Cellular Therapy. 2024-10-01
Journal Articles
- Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic LeukemiaJohn E Levine, Muna Qayed, Stephan A Grupp, Eneida R Nemecek, Stella M Davies, Michael R Verneris, Michael Boyer, Jeffrey A Engelman, Nature
Abstracts/Posters
- The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host DiseaseJohn E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...John E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationJohn E. Levine, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Everything You Need to Know About Graft-Versus-Host DiseaseJanuary 13th, 2023
- Mount Sinai Researchers Find New, Safer Treatment for Serious Side Effect of Bone Marrow TransplantDecember 13th, 2022
- An Experimental Cancer Treatment Leaves Two Patients 'Cured' After 10 YearsFebruary 18th, 2022
- Join now to see all
Grant Support
- Phase II Study Of A Novel GVHD Prevention Strategy: Etanercept And PhotopheresisNational Heart, Lung, And Blood Institute2011–2012
- Cellular Immunotherapy For Hematologic MalignancyNational Cancer Institute2001–2006
- Treatment Of Graft-Versus-Host Disease Using EnbrelFood And Drug Administration2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: